Form 4: Contineum CSO Exercises, Sells Shares Under 10b5-1 Plan

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, executed pre-planned option exercises and subsequent sales of Class A Common Stock on February 24 and 25, 2026.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), engaged in pre-scheduled transactions involving the company's Class A Common Stock.
• On February 24, 2026, Lorrain exercised options to acquire 4,300 shares at $1.01 per share and subsequently sold these 4,300 shares at a weighted average price of $16.0316 per share.
• On February 25, 2026, Lorrain exercised options to acquire 3,824 shares at $1.01 per share and subsequently sold these 3,824 shares at a weighted average price of $16.0115 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan established on September 23, 2025.
• Following these transactions, Lorrain directly beneficially owns 156,052 shares of Class A Common Stock and indirectly owns 6,842 shares through a spouse.
• The stock options exercised were fully vested and exercisable.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction under a pre-established plan, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• The transactions demonstrate the monetization of vested equity compensation by a key executive, which is a normal part of executive compensation.
• The execution of these transactions under a Rule 10b5-1 trading plan indicates pre-planning and aims to mitigate concerns about insider trading.

Negatives

• The sale of shares by a Chief Scientific Officer could be interpreted as a reduction in direct exposure to the company's stock, although this is often for personal financial planning and diversification.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that these transactions are typical for executives monetizing vested equity compensation, especially when executed under a pre-arranged 10b5-1 trading plan, which is a common practice across various industries to manage personal finances while adhering to insider trading regulations.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of a Rule 10b5-1 trading plan for executive stock transactions is a widely adopted corporate governance practice, aligning with standards seen in biotech and pharmaceutical companies like Amgen or Gilead Sciences, where executives routinely exercise options and sell shares for diversification or liquidity purposes.
• The volume of shares sold by Contineum's CSO is not unusually large compared to similar transactions by executives in companies of comparable market capitalization.

Related Party Transactions

• The reporting person indirectly beneficially owns 6,842 shares of Class A Common Stock through a spouse.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine transactions. May be viewed as a slight negative signal by some, but mitigated by the 10b5-1 plan.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

The filing details routine insider transactions (option exercise and sale) executed under a pre-established 10b5-1 trading plan. Such transactions are common for executive compensation and personal financial management and do not typically signal a change in the company's fundamental outlook or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to alter an existing investment decision.

Keywords

Contineum Therapeutics, CTNM, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Daniel S. Lorrain, Chief Scientific Officer, 10b5-1 Plan, Equity Compensation